SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Savara Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.63+0.18 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
224M of 205M shares
Institutional holders
181
25 new, 26 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $2.36M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nimish Shah | 9,021,507 | 5.20% | 13G (passive) | Jun 30, 2025 |
| Adage Capital Partners GP, L.L.C. | 7,637,930 | 5.64% | 13G (passive) amendment | Dec 31, 2023 |
| Anthony A. Florence, Jr. | 24,471,264 | 12.00% | 13D (active) amendment | Nov 12, 2025 |
| VHCP Management III, LLC | 20,881,288 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Saito Edric C. | 18,288,986 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| BCLS II Investco, LP | 17,600,621 | 9.99% | 13D (active) amendment | Mar 25, 2025 |
| Giauque, Nicolas | 15,000,000 | 6.90% | 13G (passive) amendment | Dec 31, 2025 |
| Deerfield Management Company, L.P. | 13,569,000 | 6.74% | 13G (passive) | Oct 30, 2025 |
| Chen Yu | 12,362,205 | 6.10% | 13G (passive) amendment | Dec 31, 2025 |
| Patrick J. Heron | 11,462,301 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 10,957,322 | 5.40% | 13G (passive) | Dec 31, 2025 |
| Ryan Wilder | 10,775,000 | 6.30% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SVRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 24,471,264 | 11.91% | $150.74M | – | 9.49% |
| Bain Capital Life Sciences Investors, LLC | 17,600,621 | 8.57% | $108.42M | – | 6.45% |
| VR Adviser, LLC | 14,745,943 | 7.18% | $90.84M | +1,005,568 | 2.75% |
| Nantahala Capital Management, LLC | 13,953,620 | 6.79% | $85.95M | +6,608,837 | 1.43% |
| Deerfield Management Company, L.P. (Series C) | 13,569,000 | 6.60% | $83.59M | – | 0.87% |
| BlackRock, Inc. | 12,494,498 | 6.08% | $76.97M | +1,203,313 | 0.00% |
| TCG Crossover Management, LLC | 12,362,205 | 6.02% | $76.15M | – | 1.83% |
| Frazier Life Sciences Management, L.P. | 9,720,852 | 4.73% | $59.88M | – | 1.30% |
| Polar Capital Holdings Plc | 9,541,786 | 4.64% | $58.78M | – | 0.14% |
| Vanguard Capital Management LLC | 7,932,545 | 3.86% | $48.86M | +148,632 | 0.00% |
| State Street Corp | 6,553,348 | 3.19% | $40.37M | −154,336 | 0.00% |
| Marshall Wace, Llp | 6,256,989 | 3.05% | $38.54M | +1,742,641 | 0.03% |
| Rtw Investments, LP | 5,952,380 | 2.90% | $36.67M | – | 0.31% |
| Woodline Partners LP | 4,245,119 | 2.07% | $26.15M | – | 0.08% |
| Orbimed Advisors LLC | 3,959,900 | 1.93% | $24.39M | +3,324,900 | 0.45% |
| Geode Capital Management, LLC | 3,872,133 | 1.88% | $23.86M | +277,653 | 0.00% |
| Spruce Street Capital LP | 3,452,576 | 1.68% | $21.27M | +69,401 | 4.17% |
| Rosalind Advisors, Inc. | 3,178,121 | 1.55% | $19.58M | −25,600 | 7.27% |
| Emerald Advisers, LLC | 3,148,439 | 1.53% | $19.39M | −222,846 | 0.46% |
| Pictet Asset Management Holding SA | 2,763,055 | 1.34% | $17.02M | +487,674 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 224M | 100.0% | 25 / 71 | 57 / 26 | 19M | 7M |
| Q1 2026 | 186 | 212M | 100.0% | 61 / 63 | 38 / 21 | 30M | 9M |
| Q4 2025 | 148 | 201M | 97.9% | 41 / 52 | 41 / 13 | 55M | 16M |
| Q3 2025 | 126 | 163M | 79.4% | 24 / 41 | 43 / 20 | 15M | 19M |
| Q2 2025 | 123 | 168M | 81.6% | 13 / 48 | 36 / 26 | 13M | 10M |
| Q1 2025 | 136 | 165M | 80.4% | 21 / 50 | 38 / 19 | 17M | 14M |
| Q4 2024 | 135 | 163M | 79.3% | 31 / 50 | 32 / 18 | 24M | 21M |
| Q3 2024 | 126 | 161M | 78.1% | 18 / 56 | 27 / 23 | 29M | 15M |
| Q2 2024 | 133 | 155M | 75.2% | 32 / 59 | 27 / 18 | 45M | 12M |
| Q1 2024 | 120 | 122M | 59.2% | 32 / 46 | 25 / 9 | 12M | 12M |
| Q4 2023 | 98 | 122M | 59.4% | 25 / 37 | 16 / 11 | 20M | 15M |
| Q3 2023 | 84 | 117M | 56.8% | 19 / 38 | 16 / 12 | 32M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SVRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,164,961 | 3.00% | $37.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,003,124 | 1.95% | $24.66M | 0.03% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,196,119 | 1.56% | $19.69M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,672,858 | 0.81% | $9.13M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,555,905 | 0.76% | $9.58M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,436,801 | 0.70% | $8.85M | 0.06% | Jun 30, 2026 |
| SmallCap Growth Fund I | 932,020 | 0.45% | $5.09M | 0.20% | Jul 31, 2026 |
| Emerald Growth Fund | 798,875 | 0.39% | $4.36M | 0.29% | Jul 31, 2026 |
| Emerald Growth Fund | 798,875 | 0.39% | $4.19M | 0.30% | Apr 30, 2026 |
| Vanguard Russell 2000 Index Fund | 752,873 | 0.37% | $3.91M | 0.02% | May 31, 2026 |
| iShares Biotechnology ETF | 752,380 | 0.37% | $4.63M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 704,716 | 0.34% | $3.66M | 0.01% | May 31, 2026 |
| F/m Emerald Life Sciences Innovation ETF | 651,024 | 0.32% | $3.39M | 3.22% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 646,784 | 0.31% | $3.36M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 511,820 | 0.25% | $3.15M | 0.21% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Pauls | CHIEF EXECUTIVE OFFICER, Director | 1,188,050 | 0.58% | Dec 16, 2025 |
| Braden C. Parker | Chief Commercial Officer | 75,677 | 0.04% | Sep 25, 2026 |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 328,977 | 0.16% | Jul 24, 2026 |
| David L. Lowrance | Chief Financial Officer | 953,968 | 0.46% | Jun 22, 2026 |
| Kathleen R. McCabe | Chief Legal Officer | 519,232 | 0.25% | Dec 16, 2025 |
| Anne Erickson | Chief Business Officer | 371,712 | 0.18% | Dec 16, 2025 |
| Yasmine Wasfi | Chief Medical Officer | 168,008 | 0.08% | Dec 4, 2025 |
| Raymond Dennis Pratt | Chief Medical Officer | 340,050 | 0.17% | Dec 16, 2024 |
| Joseph S. McCracken | Director | 302,644 | 0.15% | Feb 17, 2026 |
| David A. Ramsay | Director | 2,533,642 | 1.23% | Dec 19, 2025 |
| Richard J. Hawkins | Director | 161,326 | 0.08% | Dec 11, 2025 |
| Es-Johansson An van | Director | 102,500 | 0.05% | Dec 11, 2025 |
| Nevan C. Elam | Director | 106,887 | 0.05% | Dec 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Braden C. Parker Chief Commercial Officer | Sep 24, 2026 | Tax withholding | −29,323 | $5.07 | $148.67K | 75,677 |
| Robert Matthew Lutz Chief Fin. & Operating Officer | Jul 15, 2026 | Award | +35,000 | – | – | 328,977 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +218,750 | $1.51 | $330.31K | 953,968 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −53,387 | $5.50 | $293.63K | 930,560 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +87,650 | $3.35 | $293.63K | 983,947 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −10,114 | $5.50 | $55.63K | 896,297 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +12,500 | $4.45 | $55.63K | 906,411 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −60,057 | $5.50 | $330.31K | 893,911 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Sale | −394,528 | $5.68 | $2.24M | 536,032 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −11,491 | $5.50 | $63.20K | 735,218 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +56,937 | $1.11 | $63.20K | 746,709 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −28,928 | $5.50 | $159.10K | 689,772 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +129,350 | $1.23 | $159.10K | 718,700 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Tax withholding | −21,682 | $5.50 | $119.25K | 589,350 |
| David L. Lowrance Chief Financial Officer | Jun 22, 2026 | Option exercise | +75,000 | $1.59 | $119.25K | 611,032 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +75,000 | $1.59 | $119.25K | 417,555 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −24,174 | $5.04 | $121.84K | 342,555 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +80,684 | $1.51 | $121.83K | 366,729 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −9,485 | $5.04 | $47.80K | 526,237 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +43,063 | $1.11 | $47.80K | 535,722 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −11,037 | $5.04 | $55.63K | 527,700 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +24,850 | $3.35 | $83.25K | 552,550 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −16,518 | $5.04 | $83.25K | 536,032 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −23,661 | $5.04 | $119.25K | 393,894 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +130,650 | $1.23 | $160.70K | 524,544 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Tax withholding | −31,885 | $5.04 | $160.70K | 492,659 |
| David L. Lowrance Chief Financial Officer | Mar 18, 2026 | Option exercise | +12,500 | $4.45 | $55.63K | 538,737 |
| Joseph S. McCracken Director | Feb 16, 2026 | Option exercise | +1,807 | $1.76 | $3.18K | 302,644 |
| David A. Ramsay Director | Dec 19, 2025 | Sale | −20,000 | $6.06 | $121.20K | 2,533,642 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2025 | Gift | −128,995 | – | – | 1,188,050 |
| David L. Lowrance Chief Financial Officer | Dec 16, 2025 | Gift | −32,000 | – | – | 286,045 |
| Anne Erickson Chief Business Officer | Dec 14, 2025 | Tax withholding | −62,960 | $6.92 | $435.68K | 371,712 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 14, 2025 | Tax withholding | −195,705 | $6.92 | $1.35M | 1,317,045 |
| David L. Lowrance Chief Financial Officer | Dec 14, 2025 | Tax withholding | −62,960 | $6.92 | $435.68K | 318,045 |
| Robert Matthew Lutz Chief Operating Officer | Dec 14, 2025 | Tax withholding | −67,760 | $6.92 | $468.90K | 293,977 |
| Kathleen R. McCabe Chief Legal Officer | Dec 14, 2025 | Tax withholding | −39,350 | $6.92 | $272.30K | 519,232 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2025 | Gift | −23,629 | – | – | 1,512,750 |
| Nevan C. Elam Director | Dec 9, 2025 | Award | +40,000 | – | – | 106,887 |
| David A. Ramsay Director | Dec 9, 2025 | Award | +40,000 | – | – | 2,553,642 |
| Es-Johansson An van Director | Dec 9, 2025 | Award | +40,000 | – | – | 102,500 |
| Joseph S. McCracken Director | Dec 9, 2025 | Award | +40,000 | – | – | 300,837 |
| Richard J. Hawkins Director | Dec 9, 2025 | Award | +40,000 | – | – | 161,326 |
| Yasmine Wasfi Chief Medical Officer | Dec 4, 2025 | Tax withholding | −21,992 | $6.37 | $140.09K | 168,008 |
| Nevan C. Elam Director | Dec 2, 2025 | Option exercise | +5,860 | $1.46 | $8.56K | 68,360 |
| Nevan C. Elam Director | Dec 2, 2025 | Tax withholding | −1,473 | $5.81 | $8.56K | 66,887 |
| Richard J. Hawkins Director | Nov 14, 2025 | Option exercise | +5,860 | $1.46 | $8.56K | 121,326 |
| Yasmine Wasfi Chief Medical Officer | Oct 20, 2025 | Award | +35,000 | – | – | 190,000 |
| Richard J. Hawkins Director | Jun 20, 2025 | Buy | +48,225 | $2.04 | $98.38K | 115,466 |
| Joseph S. McCracken Director | May 29, 2025 | Buy | +10,000 | $2.08 | $20.80K | 260,837 |
| David A. Ramsay Director | Mar 31, 2025 | Buy | +150,000 | $2.78 | $417.00K | 2,513,642 |
| Robert Matthew Lutz Chief Operating Officer | Feb 13, 2025 | Tax withholding | −38,263 | $2.83 | $108.28K | 361,737 |
| David L. Lowrance Chief Financial Officer | Dec 16, 2024 | Sale | −25,000 | $3.33 | $83.25K | 381,005 |
| Richard J. Hawkins Director | Dec 16, 2024 | Sale | −8,000 | $3.32 | $26.56K | 67,241 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Sale | −54,702 | $3.31 | $181.06K | 1,536,379 |
| David L. Lowrance Chief Financial Officer | Dec 13, 2024 | Gift | −12,000 | – | – | 430,355 |
| David L. Lowrance Chief Financial Officer | Dec 13, 2024 | Tax withholding | −24,350 | $3.21 | $78.16K | 406,005 |
| Anne Erickson Chief Business Officer | Dec 13, 2024 | Tax withholding | −18,263 | $3.21 | $58.62K | 434,672 |
| Matthew Pauls CHIEF EXECUTIVE OFFICER, Director | Dec 13, 2024 | Tax withholding | −92,593 | $3.21 | $297.22K | 1,591,081 |
| Braden C. Parker Chief Commercial Officer | Dec 12, 2024 | Award | +20,000 | – | – | 105,000 |
| Es-Johansson An van Director | Dec 12, 2024 | Award | +40,000 | – | – | 62,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David L. Lowrance Officer | Jun 22, 2026 | 394,528 | $2.23M | Jun 22, 2026 | Cashless Stock Option Exercise |
| David A. Ramsay Director | Dec 18, 2025 | 20,000 | $122.20K | Dec 18, 2025 | Board Compensation |
| David L. Lowrance Officer | Dec 16, 2024 | 25,000 | $82.50K | Dec 16, 2024 | Vesting of RSU's |
| Matthew Pauls Director | Dec 16, 2024 | 54,702 | $180.80K | Dec 16, 2024 | Vesting of RSU's |
| Richard J. Hawkins Director | Dec 16, 2024 | 8,000 | $26.30K | Dec 16, 2024 | Vesting of RSU |
| Nevan C. Elam Director | Dec 28, 2023 | 93,843 | $448.57K | Dec 28, 2023 | CASH EXERCISE |
| Matthew Pauls Officer, Director | Dec 28, 2023 | 84,000 | $398.00K | Dec 28, 2023 | Vesting of RSU |
| David L. Lowrance Officer | Dec 28, 2023 | 10,000 | $47.40K | Dec 28, 2023 | VESTING OF RESTRICTED STOCK UNIT |